Finally, simultaneous inhibition of epidermal growth factor receptor (EGFR) and ROCK has been shown to be a promising strategy for treating triple-negative breast cancer, as revealed by shRNA screening [22]. This evidence concerns the gene EGFR and triple-negative breast carcinoma.